Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential

8. Roivant Sciences Ltd. (NASDAQ:ROIV)

Perceptive Advisors’ Stake: $173 Million

Analyst Upside Potential: 55%

Roivant Sciences Ltd. (NASDAQ:ROIV) recently won a major legal battle. In March, Roivant’s subsidiaries, Genevant and Arbutus, reached a $2.25 billion global settlement with Moderna over a COVID-19 vaccine patent. This settlement drastically improved Roivant’s balance sheet, leaving it with over $4.5 billion in cash and zero debt. Institutional investors view this as a war chest that allows the company to fund its entire pipeline through 2028 without needing to dilute shareholders with new stock offerings. These funds are also betting on Brepocitinib to be Roivant’s next multibillion-dollar success story following the sale of Telavant to Roche. In late March, the New England Journal of Medicine published positive Phase 3 VALOR trial results for Brepocitinib. The drug achieved a significant 21.6-point improvement in patient scores, which Jefferies analysts called best-in-class.

Roivant Sciences Ltd. (NASDAQ:ROIV) stock has surged since the FDA recently granted Priority Review for Brepocitinib in dermatomyositis, with a target action date in Q3 2026. Top funds are buying the shares ahead of this potential September launch. The firm also has a shareholder-friendly capital allocation strategy. Roivant completed a $1 billion share repurchase program in late 2025/early 2026, retiring approximately 150 million shares, over 15% of the company. Large-scale buybacks are a major attractant for funds as they increase the slice of the pie for remaining shareholders as the company’s valuation grows. Another catalyst is that the company owns a majority stake in Immunovant, which is developing IMVT-1402, a potential best-in-class treatment for autoimmune diseases.